Sarepta Therapeutics Shares Hit Nine-Year Low Following Second Patient Death Linked to Elevidys
Sarepta Therapeutics experienced a significant drop in stock value on Monday, falling nearly 50% after the announcement of a second patient death linked to its Elevidys drug, which is intended for treating Duchenne muscular dystrophy.










